I think the problem is that there has been a conflation of the push and pull speculation and counterpoints made regarding the rapid antigen tests purchased by the UK with the market for these antibody products. As pointed out by a number of folks, as yet, the former does not appear to utilize QMC so it's possible these serology tests end up leading the way in the short term. To date, they have obviously not generated enough dollars to overcome the need for additional debt and sale of the company.